Oncotarget

Research Papers:

Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis

Meng Ye _, Tao Huang, Ying Ying, Jinyun Li, Ping Yang, Chao Ni, Chongchang Zhou and Si Chen

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:9230-9242. https://doi.org/10.18632/oncotarget.13992

Metrics: PDF 2217 views  |   HTML 2528 views  |   ?  


Abstract

Meng Ye1, Tao Huang1, Ying Ying3, Jinyun Li1, Ping Yang1,2, Chao Ni1,2, Chongchang Zhou2, Si Chen1

1The Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315020, People’s Republic of China

2Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, People’s Republic of China

3Ningbo No. 2 Hospital, Ningbo, Zhejiang 315010, People’s Republic of China

Correspondence to:

Meng Ye, email: yemeng@nbu.edu.cn

Tao Huang, email: huangtao334@163.com

Keywords: 14-3-3 σ, promoter methylation, breast cancer, blood, diagnosis, biomarker

Received: September 27, 2016     Accepted: December 12, 2016     Published: December 16, 2016

ABSTRACT

As a tumor suppressor gene, 14-3-3 σ has been reported to be frequently methylated in breast cancer. However, the clinical effect of 14-3-3 σ promoter methylation remains to be verified. This study was performed to assess the clinicopathological significance and diagnostic value of 14-3-3 σ promoter methylation in breast cancer. 14-3-3 σ promoter methylation was found to be notably higher in breast cancer than in benign lesions and normal breast tissue samples. We did not observe that 14-3-3 σ promoter methylation was linked to the age status, tumor grade, clinic stage, lymph node status, histological subtype, ER status, PR status, HER2 status, or overall survival of patients with breast cancer. The combined sensitivity, specificity, AUC (area under the curve), positive likelihood ratios (PLR), negative likelihood ratios (NLR), diagnostic odds ratio (DOR), and post-test probability values (if the pretest probability was 30%) of 14-3-3 σ promoter methylation in blood samples of breast cancer patients vs. healthy subjects were 0.69, 0.99, 0.86, 95, 0.31, 302, and 98%, respectively. Our findings suggest that 14-3-3 σ promoter methylation may be associated with the carcinogenesis of breast cancer and that the use of 14-3-3 σ promoter methylation might represent a useful blood-based biomarker for the clinical diagnosis of breast cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13992